Name of opportunity: 👀
ProQR Therapeutics NV
Medical innovation: 🆕
Data from a clinical trial has been described as providing “proof of mechanism” that RNA editing might be able to help treat rare genetic conditions. These treatments might be able to correct mutations, limiting symptoms or even reversing a condition. The trial showed that RNA editing was able to boost the levels of a specific protein that people with Alpha-1 Antitrypsin Deficiency (AATD) are lacking. ATTD is a rare genetic disorder that can affect the lungs and liver.
While the trial was carried out by rival Wave Life Sciences Ltd, fellow drug developers Korro in the space Bio Inc and ProQR Therapeutics also saw the price of their stocks dramatically jump. ProQR Therapeutics is currently considered to be a ‘Buy’.
How hot is this investment opportunity? 🔥🔥🔥
Analysts predict the price of ProQR Therapeutics NV might increase from $1.89 to $4.25 in the next 12 months. If you invested $1000, you might profit $1254.64 - that’s a potential increase of 125.46%!
Since the recent news about the RNA editing technology breakthrough, ProQR has already increased in value by 125.13%.
The reason the stock’s current price might further increase by such a high margin is that it is currently priced very low - it’s currently a ‘penny stock’. This means that even an increase of a few dollars would more than double its current price.
ProQR Therapeutics are currently developing their own proprietary RNA editing technology called Axiomer™, which the company hopes will be able to treat currently untreatable diseases. ProQR may become a leader in this space. The huge drug developer Eli Lilly has provided funding in 2021 and 2022, in a collaboration in which the two companies would use the Axiomer™ tech to research disorders of the liver and nervous system.
Biotech: 🩺
ProQR Therapeutics NV is a pre-clinical stage biopharmaceutical company based in the Netherlands. The company is engaged in the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It was founded in 2012 by current CEO, Daniel A. de Boer.
Which neme?: 🔍
Search directly for ProQR
Download Nemo to check out ProQR Therapeutics
